ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has form...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Informa Healthcare
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554/ |